Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CD | O00329 | 2/20 | 0.43 |
| ▸ | GPR119 | Q8TDV5 | 3/20 | 0.42 |
| ▸ | IDO1 | P14902 | 1/20 | 0.42 |
| ▸ | TDO2 | P48775 | 1/20 | 0.42 |
| ▸ | USP30 | Q70CQ3 | 4/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.41 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | PKM | P14618 | 1/20 | 0.40 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.40 |
| ▸ | FAAH | O00519 | 1/20 | 0.39 |
| ▸ | STS | P08842 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21603203 | 1.00 | PIK3CD (0.43) | PIK3CDGPR119IDO1TDO2USP30 | |
| SCHEMBL20281810 | 1.00 | PIK3CD (0.43) | PIK3CDGPR119IDO1TDO2USP30 | |
| SCHEMBL21605749 | 0.94 | CYP2C9 (0.43) | USP30ALDH1A1KDM4E | |
| SCHEMBL21604507 | 0.94 | CYP2C9 (0.43) | USP30ALDH1A1KDM4E | |
| SCHEMBL20281825 | 0.91 | PIK3CD (0.47) | PIK3CDGPR119IDO1TDO2USP30 | |
| SCHEMBL21603175 | 0.91 | PIK3CD (0.47) | PIK3CDGPR119IDO1TDO2USP30 | |
| SCHEMBL21603190 | 0.91 | PIK3CD (0.47) | PIK3CDGPR119IDO1TDO2USP30 | |
| SCHEMBL20281798 | 0.90 | PIK3CD (0.46) | PIK3CDGPR119IDO1TDO2USP30 | |
| SCHEMBL21607866 | 0.87 | LOXL2 (0.42) | PIK3CDGPR119IDO1TDO2USP30 | |
| SCHEMBL20281615 | 0.87 | LOXL2 (0.42) | PIK3CDGPR119IDO1TDO2USP30 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210300900-A1 | OGA INHIBITOR COMPOUNDS | JANSSEN PHARMACEUTICA NV (BE) | 2021-09-30 | — | — | US | disclosed |
| US-20210277015-A1 | OGA INHIBITOR COMPOUNDS | JANSSEN-CILAG S.A. (ES) | 2021-09-09 | — | — | US | disclosed |
| US-20210115040-A1 | OGA INHIBITOR COMPOUNDS | JANSSEN PHARMACEUTICA NV (BE) | 2021-04-22 | — | — | US | disclosed |
| WO-2019243527-A1 | OGA INHIBITOR COMPOUNDS | JANSSEN PHARMACEUTICA NV (BE) | 2019-12-26 | — | — | WO | disclosed |
| WO-2019243531-A1 | OGA INHIBITOR COMPOUNDS | JANSSEN PHARMACEUTICA NV (BE) | 2019-12-26 | — | — | WO | disclosed |
| WO-2019243528-A1 | OGA INHIBITOR COMPOUNDS | JANSSEN PHARMACEUTICA NV (BE) | 2019-12-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210277015-A1 | OGA INHIBITOR COMPOUNDS | OGA, OGT, GRN | PIK3CD 1988/4885GPR119 1166/4885IDO1 2139/4885 |
| US-20210115040-A1 | OGA INHIBITOR COMPOUNDS | OGA, OGT, GRN | PIK3CD 1988/4885GPR119 1166/4885IDO1 2139/4885 |
| US-20210300900-A1 | OGA INHIBITOR COMPOUNDS | OGA, OGT, GRN | PIK3CD 1988/4885GPR119 1166/4885IDO1 2139/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.